Table 7.
The comparison of SLE patients with pulmonary fibrosis in relation to immunosuppressive treatment
| Parameter | With immunosuppressive treatment (n = 16) | Without immunosuppressive treatment (n = 18) | p value |
|---|---|---|---|
| SLAM | 10.75 ± 3.88 | 7.55 ± 1.23 | ns |
| Time of SLE duration (years) | 12.0 ± 6.48 | 8.57 ± 9.50 | ns |
| Lymphocytes % BALF | 18.50 ± 12.72 | 22.88 ± 12.23 | ns |
| Eosinophils % BALF | 1.44 ± 2.55 | 0.12 ± 0.35 | ns |
| Neutrophils % BALF | 7.37 ± 10.37 | 3.11 ± 4.98 | ns |
| Macrophages % BALF | 77.42 ± 14.19 | 72.22 ± 15.77 | ns |
| FEV1/FVC (%) | 79.12 ± 7.18 | 85.62 ± 8.15 | ns |
| FVC (%pred.) | 78.71 ± 23.76 | 106.00 ± 11.25 | p < 0.05 |
| FEV1 (%pred.) | 73.37 ± 18.67 | 101.75 ± 12.03 | p < 0.01 |
| TLC (%pred.) | 81.71 ± 16.34 | 97.50 ± 13.18 | ns (p = 0.052) |
| DLCOc (%pred.) | 98.87 ± 20.06 | 87.77 ± 13.85 | ns |
| IL-8 BALF (pg/ml) | 81.38 ± 81.23 | 29.61 ± 19.14 | p < 0.05 |
| IL-8 EBC (pg/ml) | 3.76 ± 0.44 | 3.87 ± 0.38 | ns |
Values are given as the mean ± SD
BALF bronchoalveolar lavage fluid, DLCOc diffusion capacity for carbon monoxide corrected for hemoglobin concentration; EBC exhaled breath condensate, FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, ns not significant, SLAM systemic lupus activity measure, TLC total lung capacity, %pred. % predicted